Co-diagnostics, INC Form 4 insider transactions

Co-Diagnostics CEO, Dwight H. Egan, acquired 163,333 shares of common stock through vesting of restricted stock units and sold 49,689 shares to cover tax obligations.

Director Ted Murphy of Co-Diagnostics, Inc. acquired 48,333 shares of common stock through the vesting of restricted stock units on November 23, 2024.

Director Eugene Durenard acquired 48,333 shares of Co-Diagnostics stock through the vesting of restricted stock units.

Director James Nelson of Co-Diagnostics, Inc. acquired 48,333 shares of common stock through the vesting of restricted stock units on November 23, 2024.

Director Richard Serbin acquired 48,333 shares of Co-Diagnostics stock through the vesting of restricted stock units.

Brian Lee Brown, CFO of Co-Diagnostics, Inc., reports the acquisition and disposition of company stock and restricted stock units to cover tax obligations.

CEO Dwight Egan reports acquisition of 138,333 shares via restricted stock units and disposition of 42,008 shares to cover tax obligations.

Director Ted Murphy acquired 30,000 shares of Co-Diagnostics common stock and disposed of 30,000 restricted stock units on May 23, 2024.

Director James Nelson acquired 30,000 shares of Co-Diagnostics common stock on May 23, 2024, through the vesting of restricted stock units.

Director Richard Serbin acquired 30,000 shares of Co-Diagnostics, Inc. common stock on May 23, 2024.

Director Eugene Durenard acquired 30,000 shares of Co-Diagnostics common stock on May 23, 2024, increasing his direct holdings to 115,000 shares.

Richard David Abbott, President of Co-Diagnostics, Inc., reports the acquisition of 120,000 Restricted Stock Units (RSUs) on April 26, 2024.

Brian Lee Brown, CFO of Co-Diagnostics, Inc., reports the acquisition of 225,000 restricted stock units (RSUs) on April 26, 2024.

Dwight H. Egan, CEO of Co-Diagnostics, Inc., reports the acquisition of 275,000 restricted stock units (RSUs) on April 26, 2024, according to a Form 4 filing with the SEC.

Director Eugene Durenard of Co-Diagnostics, Inc. (CODX) was granted 110,000 restricted stock units (RSUs) on April 26, 2024, under the company's 2015 Long Term Incentive Plan.

Director Richard Serbin of Co-Diagnostics, Inc. was granted 110,000 restricted stock units (RSUs) on April 26, 2024, according to a Form 4 filing with the SEC.

Director Ted Murphy reports acquisition of 110,000 Restricted Stock Units in Co-Diagnostics, Inc.

Director James B. Nelson of Co-Diagnostics, Inc. reports the acquisition of 110,000 restricted stock units (RSUs) on April 26, 2024, under the company's 2015 Long Term Incentive Plan.